Synlogic (Synlogic) Debt-to-Equity : 0.41 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Synlogic Debt-to-Equity?

Synlogic's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $4.78 Mil. Synlogic's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $12.49 Mil. Synlogic's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $42.66 Mil. Synlogic's debt to equity for the quarter that ended in Dec. 2023 was 0.40.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Synlogic's Debt-to-Equity or its related term are showing as below:

SYBX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.15 Max: 0.41
Current: 0.41

During the past 12 years, the highest Debt-to-Equity Ratio of Synlogic was 0.41. The lowest was 0.00. And the median was 0.15.

SYBX's Debt-to-Equity is ranked worse than
71.99% of 1071 companies
in the Biotechnology industry
Industry Median: 0.15 vs SYBX: 0.41

Synlogic Debt-to-Equity Historical Data

The historical data trend for Synlogic's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synlogic Debt-to-Equity Chart

Synlogic Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.16

0.20

0.14

0.25

0.41

Synlogic Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.25	0.28	0.35	0.42	0.41

Competitive Comparison of Synlogic's Debt-to-Equity

For the Biotechnology subindustry, Synlogic's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Synlogic's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Synlogic's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Synlogic's Debt-to-Equity falls into.

Synlogic Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Synlogic's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.784	+	12.491)	/	42.655
	=	0.40

Synlogic's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.784	+	12.491)	/	42.655
	=	0.40

Synlogic (NAS:SYBX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Synlogic Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Synlogic's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Synlogic (Synlogic) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synlogic Inc (NAS:SYBX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

301 Binney Street, Suite 402, Cambridge, MA, USA, 02142

Website

https://www.synlogictx.com

Synlogic Inc is a biopharmaceutical company focused on the discovery and development of Synthetic Biotic medicines that are designed to metabolize a toxic substance, compensate for missing or damaged metabolic pathways, or deliver combinations of therapeutic factors. Synthetic Biotic medicines are generated from the company's proprietary drug discovery and development platform, using Synthetic Biology and leveraging a reproducible, modular approach to develop beneficial microbes that perform or deliver critical therapeutic functions. Its key product candidate is SYNB1618, an oral therapy intended for the treatment of PKU, a rare metabolic disease in which an amino acid known as phenylalanine accumulates in the body as a result of genetic defects.

Executives

Michael Vangsted Jensen	officer: Chief Financial Officer	301 BINNEY STREET, SUITE 402, CAMBRIDGE MA 02142
Aoife Brennan	officer: Chief Medical Officer	200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Antoine Awad	officer: Chief Operating Officer	C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE MA 02142
Lisa Kelly-croswell	director	C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE MA 02142
Michael Thomas Heffernan	director	C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Michael F. Burgess	director	C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMRIDGE MA 02142
Richard P Shea	director	C/O MOMENTA PHARMACEUTICALS, INC., 43 MOULTON STREET, CAMBRIDGE MA 02138
Gregg Beloff	officer: See Remarks	C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Richard J. Riese	officer: Chief Medical Officer	C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE MA 02142
Ginkgo Bioworks, Inc.	10 percent owner	27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON MA 02210
Scott Eric Plevy	officer: Chief Scientific Officer	301 BINNEY STREET, #402, C/O SYNLOGIC, INC., CAMBRIDGE MA 02142
Paul Francis Miller	officer: Chief Scientific Officer	200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Patricia N. Hurter	director	C/O SYNLOGIC, INC., 301 BINNEY ST., SUITE 402, CAMBRIDGE MA 02142
Andrew Gengos	officer: See Remarks	21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Todd Shegog	officer: See Remarks	200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139